# HARMONi-2 survival data: ivonescimab cuts risk of death by 27% versus Keytruda

Canonical page: https://technooptimist.io/stories/harmoni-2-survival-data-ivonescimab-cuts-risk-of-death-by-27-versus-936c243d
Date: 15 Sep 2026
About: [Summit Therapeutics](https://technooptimist.io/companies/summit-therapeutics.md) · [Ivonescimab](https://technooptimist.io/biotech/ivonescimab.md)
Original source: https://ascopost.com/news/september-2026/ivonescimab-significantly-improves-overall-survival-vs-pembrolizumab-in-pd-l1-positive-advanced-nsclc/

At the 2026 World Conference on Lung Cancer, investigators reported that ivonescimab alone extended overall survival compared with Keytruda alone in PD-L1-positive advanced lung cancer in the China HARMONi-2 trial. Median survival was 30.8 months versus 22.6 months. Survival was a key secondary endpoint; the trial had already won on progression-free survival.

## Key facts

- Overall survival HR 0.73 (95% CI 0.57–0.95; p=0.009), 234 deaths at the 20 Aug 2026 cutoff.
- Strongest benefit in squamous tumours (HR 0.65) and high PD-L1 (HR 0.58); several subgroup intervals cross 1.
- Serious treatment-related side effects 29.9% vs 21.6%; discontinuation 4.1% vs 5.0%.
- China approved ivonescimab for this population in April 2025.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.